Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 714M 617M 577M 529M 995M 67.94B 1.01B 6.77B 2.66B 34.05B 2.68B 2.62B 113B P/E 2026 *
3.63x
P/E 2027 * 3.51x
Enterprise Value 714M 617M 577M 529M 995M 67.94B 1.01B 6.77B 2.66B 34.05B 2.68B 2.62B 113B EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.49x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week+2.13%
Current month+2.13%
1 month-3.36%
3 months+3.60%
6 months-5.26%
Current year+28.19%
1 week 3.92
Extreme 3.92
4.59
1 month 3.55
Extreme 3.55
4.78
Current year 2.95
Extreme 2.95
5.78
1 year 0.81
Extreme 0.81
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 19/07/2026
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
23/02/26 Sell

Chief Executive Officer

198,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%+2.13%+390.91%-61.94% 701M
+0.16%-1.24%+59.99%+21.20% 317B
-1.03%+0.35%+37.33%-10.25% 72.72B
+20.24%+24.93%+66.05%+145.47% 10.17B
+1.29%-0.31%-5.23%-4.32% 8.31B
+2.28%+8.10%-14.26%-6.67% 4.6B
+3.60%+9.66%-28.16%+15.93% 4.08B
+14.37%+22.10%+4.12%+59.93% 3.83B
+1.88%+6.74%+14.91%+47.72% 2.72B
+4.26%+0.31%+0.91%-0.41% 2.16B
Average +4.85%+6.69%+52.66%+20.67% 42.63B
Weighted average by Cap. +0.68%+0.06%+52.81%+18.22%

Financials

2026 *2027 *
Net sales 465M 402M 375M 344M 648M 44.22B 658M 4.4B 1.73B 22.17B 1.74B 1.71B 73.28B 478M 413M 386M 354M 666M 45.44B 676M 4.53B 1.78B 22.78B 1.79B 1.75B 75.3B
Net income 200M 173M 162M 149M 279M 19.08B 284M 1.9B 746M 9.56B 753M 736M 31.62B 210M 182M 170M 156M 293M 19.99B 297M 1.99B 781M 10.02B 789M 771M 33.12B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
07/08/26 US$4.320 +1.41% 1,841,621
06/08/26 US$4.260 +2.65% 3,361,970
05/08/26 US$4.150 -3.71% 2,209,855
04/08/26 US$4.310 -2.49% 5,768,302
03/08/26 US$4.420 +4.49% 3,818,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.320USD
Average target price
6.100USD
Spread / Average Target
+41.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock